Group Financial Reporting Manager

OXB; Oxford; On-site; GBP 150,000 - 200,000; Full time

Job summary

A leading viral vector CDMO in Oxford is looking for a Group Financial Reporting Manager to oversee global department reporting and technical accounting. The ideal candidate should be a qualified accountant with strong skills in IFRS and ERP systems. Responsibilities include managing month-end close processes and maintaining stakeholder relationships. The company offers competitive rewards and a collaborative work culture focused on making a difference in patient therapies.

Benefits

Competitive total reward packages

Wellbeing programs

Career development opportunities

Supportive and inclusive culture

Qualifications

• Proven experience as a qualified accountant working within finance or an accounting practice.
• Good understanding of financial reporting and processes in a business environment.
• Good knowledge and experience of ERP systems processes and transactions.

Responsibilities

• Advising on technical issues and maintaining external reporting compliance.
• Managing the Group Month End Close process and Group’s Balance Sheet and Cash flow.
• Maintaining relationships with stakeholders across the Global business.

Skills

Qualified Accountant

Strong technical experience with IFRS 15

Good Microsoft Office skills with advanced skills in MS Excel

Strong communicator

Ability to adapt to change

Education

Qualified Accountant certification

Tools

ERP systems

Job description

Job Description

Join Us in Changing Lives

At OXB, our people are at the heart of everything we do. We’re on a mission to enable life‑changing therapies to reach patients around the world—and we’re looking for passionate individuals who embody our core values every day: Responsible, Responsive, Resilient, and Respectful.

Group Financial Reporting Manager

We are currently recruiting for a Group Financial Reporting Manager to join the Finance team. The Group Financial Reporting Manager plays a central role within finance, with responsibility for Global department reporting, technical accounting matters, Group taxation, Foreign exchange hedging and treasury. Our Finance team provide financial reporting, control, and accountancy across the business.

Responsibilities

• Primary responsibility for advising on technical issues, preparing the IFRS Accounting Papers and maintaining external reporting compliance
• Managing the Group Month End Close process including the Group Consolidation entries and Intercompany; reporting on Group departments and has responsibility for Group’s Balance Sheet and Cash flow.
• Group taxation including transfer pricing, Group Treasury lead including foreign exchange hedging and a key contributor in Internal Control Compliance.
• Responsible for maintaining relationships with stakeholders across the Global business to support the compliant consolidation of the externally reported numbers

Profile description

• Qualified Accountant.
• Proven experience as a qualified accountant working within finance or an accounting practice.
• Strong technical experience with IFRS 15.
• Good understanding of financial reporting and processes in a business environment
• Good knowledge and experience of ERP systems processes and transactions
• Good Microsoft Office skills with advanced skills in MS Excel.
• Strong communicator with the ability to build relationships cross functionally.
• Ability to adapt to change in an agile way.

About us

OXB is a quality and innovation‑led viral vector CDMO with a mission to enable its clients to deliver life‑changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno‑associated virus (AAV) and adenoviral vectors. OXB’s world‑class capabilities span from early‑stage development to commercialisation. These capabilities are supported by robust quality‑assurance systems, analytical methods, and depth of regulatory expertise.

Why join us?

• Competitive total reward packages
• Wellbeing programs that support your mental and physical health
• Career development opportunities to help you grow and thrive
• Supportive, inclusive, and collaborative culture
• State‑of‑the‑art labs and manufacturing facilities
• A company that lives its values: Responsible, Responsive, Resilient, Respect

We want you to feel inspired every day. At OXB, we’re future‑focused and growing fast. We succeed together—through passion, commitment, and teamwork.

Ready to Make a Difference?

Collaborate. Contribute. Change lives.

We offer

Oxford Biomedica is a quality and innovation‑led viral vector CDMO that enables its clients to deliver life‑changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re‑engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (ex vivo gene therapy or gene‑modified cell therapy).

Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno‑associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world‑class capabilities span from early‑stage development to commercialisation. These capabilities are supported by robust quality‑assurance systems, analytical methods and depth of regulatory expertise.